163759-94-2

Basic information

• Product Name: N4-Benzoyl-5'-O-DMT-2'-O-methylcytidine 3'-CE phosphoramidite
• Synonyms: N4-Benzoyl-5'-O-DMT-2'-O-methylcytidine 3'-CE phosphoramidite;Cytidine, N-benzoyl-5'-O-[bis(4-Methoxyphenyl)phenylMethyl]-2'-O-(2-Methoxyethyl)-5-Methyl-, 3'-[2-cyanoethyl bis(1-Methylethyl)phosphoraMidite];N-Benzoyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-O-(2-methoxyethyl)-5-methylcytidine 3'-[2-cyanoethyl N,N-bis(1-methylethyl)phosphoramidite];2'-O-MOE-5Me-C(Bz)-3'-phosphoramidite;N4-Benzoyl-5'-O-(4,4'-dimethoxytrityl)-2'-O-methylcytidine-3'-(2-cyanoethyl diisopropylphosphoramidite);N4-Bz-5'-O-DMTr-2'-O-(2-methoxyethyl)-5-methylcytidine-3'-CED-phosphoramidite;N4-Benzoyl-5'-O-DMT-2'-O-(2-methoxyethyl)-5-methylcytidine 3'-CE phosphoramidite
• CAS NO: 163759-94-2
• Molecular Formula: C47H54N5O9P
• Molecular Weight: 863.933521
• Mol File: 163759-94-2.mol
• Article Data: 89

Chemical Properties

• Appearance: White to Off-white/Powder
• PKA: 8.59±0.40(Predicted)
• CAS DataBase Reference: N4-Benzoyl-5'-O-DMT-2'-O-methylcytidine 3'-CE phosphoramidite(CAS DataBase Reference)
• NIST Chemistry Reference: N4-Benzoyl-5'-O-DMT-2'-O-methylcytidine 3'-CE phosphoramidite(163759-94-2)
• EPA Substance Registry System: N4-Benzoyl-5'-O-DMT-2'-O-methylcytidine 3'-CE phosphoramidite(163759-94-2)

Safety Data

• Hazardous Substances Data: 163759-94-2(Hazardous Substances Data)

Usage

Uses

N4-Benzoyl-5''-O-DMT-2''-O-methylcytidine 3''-CE phosphoramidite (CAS# 163759-94-2) is a nucleotide used in the stereoselective synthesis of nucleoside alkyl-phosphonates.

Upstream product

• 40615-36-9 4,4'-dimethoxytrityl chloride 
• 163759-49-7 2'-O-(2-methoxyethyl)-5-methyluridine 
• 163759-50-0 5'-O-(4,4'-dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-5-methyluridine 
• 102691-36-1 N,N,N',N'-tetraisopropyl 2-cyanoethylphosphorodiamidite 
• 182496-00-0 2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine 
• 22423-26-3 O-2,2'-cyclo-5-methyluridine 
• 93-97-0 benzoic acid anhydride 
• 182496-01-1 5'-O-(4,4'-dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-N₄-benzoyl-5-methylcytidine 
• 133485-25-3 bis(diisopropylamino)(2-cyanoethoxy)phosphane 
• 292037-80-0 N⁴-benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine 
• 253156-63-7 2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine 
• 93183-36-9 N,N-diisopropylamine tetrazolide 

Relevant articles and documents

METHODS FOR THE PREVENTION AND TREATMENT OF MAJOR ADVERSE CARDIOVASCULAR EVENTS USING COMPOUNDS THAT MODULATE APOLIPOPROTEIN B

Provided herein, for example, are methods generally relating to preventing, treating and/or managing a major adverse cardiovascular event in a subject with a disease or condition at risk for a major adverse cardiovascular event, e.g., familial hypercholesterolemia. Also provided herein are methods relating to administering to the patient a therapeutically effective amount of an antisense oligonucleotide having a nucleobase SEQ ID NO: 247 (e.g., mipomersen).

Modulation of DC-SIGN expression

Compounds, compositions and methods are provided for modulating the expression of DC-SIGN. The compositions comprise oligonucleotides, targeted to nucleic acid encoding DC-SIGN. Methods of using these compounds for modulation of DC-SIGN expression and for diagnosis and treatment of diseases and conditions associated with expression of DC-SIGN are provided.

Antisense inhibition via RNAse H-independent reduction in mRNA

The present invention provides compositions and methods for reducing levels of a preselected mRNA, using antisense compounds targeted to a splice site or a region up to 50 nucleobases upstream of an exon/intron junction on said mRNA. Preferably, said antisense compounds do not elicit RNAse H cleavage of the mRNA.